




RealRate

PHARMACEUTICAL 2015

Tobira Therapeutics Inc
Rank 178 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tobira Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tobira Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Tobira Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 43% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	54,158
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,120
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-14,840
Other Expenses	0
Other Liabilities	0
Other Net Income	-487
Other Revenues	0
Property and Equipment	239
Research and Development	54,926
Selling, General and Administrative Expense	11,699

Output Variable	Value in 1000 USD
Assets	54,397
Liabilities	9,120
Expenses	66,625
Revenues	0
Stockholders Equity	45,277
Net Income	-67,112
Comprehensive Net Income	-74,532
BaseVar	72,734
ECR before LimitedLiability	76%
Economic Capital Ratio	211%